Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Hepalatide in Healthy Volunteers
NCT02612506Phase 1Completed
- Sponsor
- Shanghai Hepu Pharmaceutical
- Start
- Oct 2015
- Primary completion
- Aug 2016
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing Hepalatide with Placebo (2 arms). Primary endpoint: Treatment-related adverse events at 6 months. Started Oct 2015; status: completed.
02
Drugs
hepalatide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02612506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612506.